CUE - Cue Biopharma, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
13.56
+1.16 (+9.35%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close12.40
Open12.37
Bid13.51 x 800
Ask13.61 x 3200
Day's range11.60 - 13.71
52-week range4.16 - 13.71
Volume1542882
Avg. volume127,287
Market cap312M
Beta (5Y Monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.87
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.00
  • The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
    Zacks

    The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

    The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

  • 5 Biotech Stocks Up More Than 100% This Year So Far
    Zacks

    5 Biotech Stocks Up More Than 100% This Year So Far

    The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.

  • Here's Why Cue Biopharma, Inc. (CUE) is a Great Momentum Stock to Buy
    Zacks

    Here's Why Cue Biopharma, Inc. (CUE) is a Great Momentum Stock to Buy

    Does Cue Biopharma, Inc. (CUE) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Cue Biopharma, Inc. (CUE) Shares March Higher, Can It Continue?
    Zacks

    Cue Biopharma, Inc. (CUE) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Cue Biopharma, Inc. (CUE).

  • GlobeNewswire

    Cue Biopharma to Present at the World Vaccine & Immunotherapy Congress

    CAMBRIDGE, Mass., Dec. 02, 2019 -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to.

  • What Makes Cue Biopharma, Inc. (CUE) a New Strong Buy Stock
    Zacks

    What Makes Cue Biopharma, Inc. (CUE) a New Strong Buy Stock

    Cue Biopharma, Inc. (CUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).

  • GlobeNewswire

    Cue Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    Initiated patient dosing in Phase 1 clinical study of lead program CUE-101 in head and neck squamous cell carcinoma (HNSCC)Extended cash runway with $11.9 million from.

  • GlobeNewswire

    Cue Biopharma to Present at Upcoming Investor Conferences in November 2019

    Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will present at the Oncology Investor Conference on Wednesday, November 13, 2019 In New York and Stifel Healthcare Conference on Wednesday, November 20, 2019 in New York. Daniel Passeri, chief executive officer of Cue Biopharma, will provide an overview of the Immuno-STAT™ (Selective Targeting and Alteration of T cells) biologics platform for selective modulation of disease relevant T cells within the patient’s body.

  • GlobeNewswire

    Cue Biopharma to Host Business Update Call and Webcast

    Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will host a conference call and webcast to provide a business update on Tuesday, November 12, 2019 at 4:30 p.m. ET. Members of the Cue Biopharma executive management team will provide an update on the ongoing Phase 1 clinical trial for the company’s lead program CUE-101 and give an overview of the clinical development plan and strategy for this potential drug candidate. Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases.

  • Here's Why We're Watching Cue Biopharma's (NASDAQ:CUE) Cash Burn Situation
    Simply Wall St.

    Here's Why We're Watching Cue Biopharma's (NASDAQ:CUE) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • GlobeNewswire

    Cue Biopharma Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

    Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will deliver a poster presentation on its lead program, CUE-101, at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019). SITC is being held on November 6-10, 2019 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland. The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules.

  • GlobeNewswire

    Cue Biopharma to Present at the Oppenheimer Houston Oncology Summit at the University of Texas MD Anderson Cancer Center

    Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will present at the Houston Oncology Summit at the University of Texas MD Anderson Cancer Center on Thursday, October 17, 2019 at 10:40 a.m. CT in Houston, Texas. Daniel Passeri, chief executive officer of Cue Biopharma, will provide an overview of the clinical development plan and strategy for the company’s lead program CUE-101, which is currently being tested in a Phase 1 clinical trial for the treatment of HPV16-driven recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

  • GlobeNewswire

    Cue Biopharma Announces Changes to its Board of Directors

    Cue Biopharma, Inc. (CUE) a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today changes to its board of directors. Anthony DiGiandomenico has stepped down from the board and Aaron Fletcher, Ph.D. has been appointed, as the company executes its next phase of growth. Mr. DiGiandomenico joined Cue Biopharma as a director in June 2015, shortly after the company’s founding.

  • GlobeNewswire

    Cue Biopharma to Present at Upcoming October 2019 Scientific Conferences

    CAMBRIDGE, Mass., Oct. 09, 2019 -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to.

  • GlobeNewswire

    Cue Biopharma Promotes Dr. Anish Suri to President and CSO

    Cue Biopharma, Inc. (CUE) a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today the promotion of Anish Suri, Ph.D., to the role of president in addition to his current role as chief scientific officer.

  • GlobeNewswire

    Cue Biopharma to Present Corporate Overview and Update on Clinical Development Progress for CUE-101 at the Cantor 2019 Global Healthcare Conference

    Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will present at the Cantor 2019 Global Healthcare Conference on Wednesday, October 2, 2019 at 4:10 p.m. ET in New York City. Daniel Passeri, president and chief executive officer of Cue Biopharma, will provide a corporate overview and update on the clinical development progress for the Company’s lead program CUE-101, which is currently being tested in a Phase 1 clinical trial for the treatment of HPV16-driven recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

  • GlobeNewswire

    Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma

    Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that on September 23, 2019 it dosed the first patient in a Phase 1 clinical trial of CUE-101 at Washington University, Alvin J. Siteman Cancer Center, St. Louis, Missouri for the treatment of HPV16-driven recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Enabled by the company’s proprietary Immuno-STAT™ (Selective Targeting and Alternation of T cells) platform, CUE-101 is the company’s lead biologic drug candidate from the IL-2 based CUE-100 series, designed to directly engage and activate T cells in the body to target HPV-driven cancers.

  • Read This Before Selling Cue Biopharma, Inc. (NASDAQ:CUE) Shares
    Simply Wall St.

    Read This Before Selling Cue Biopharma, Inc. (NASDAQ:CUE) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Do Insiders Own Shares In Cue Biopharma, Inc. (NASDAQ:CUE)?
    Simply Wall St.

    Do Insiders Own Shares In Cue Biopharma, Inc. (NASDAQ:CUE)?

    The big shareholder groups in Cue Biopharma, Inc. (NASDAQ:CUE) have power over the company. Generally speaking, as a...

  • GlobeNewswire

    Cue Biopharma to Present Corporate Overview & Clinical Strategy for CUE-101 at Jefferies 2019 Healthcare Conference

    Cue Biopharma, Inc., (CUE) an innovative clinical stage immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today it will present a corporate overview and update at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019 at 3:00 pm ET in New York City. Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer, will provide an overview of the translational-based clinical strategy for the Company’s lead program CUE-101, that recently received IND acceptance from the FDA. The presentation will also be archived for 30 days on the Investors section of the Company's website at www.cuebio.com.

  • GlobeNewswire

    Cue Biopharma Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, CUE-101, in Treatment of HPV-driven Cancers

    Cue Biopharma, Inc., (CUE), an innovative clinical stage immunotherapy company, developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for its lead immuno-oncology candidate, CUE-101, an Immuno-STAT™ (Selective Targeting and Alteration of T cells) biologic, as a potential treatment for HPV-associated cancers. “FDA acceptance of our IND filing for CUE-101 is an important step toward validating our approach for selective modulation of disease-relevant T cells directly in patients with an “off-the shelf” biologic.

  • GlobeNewswire

    Dr. Anish Suri, Cue Biopharma’s CSO, to Participate in Panel Discussion at Upcoming NYAS Frontiers in Cancer Immunotherapy Conference

    Cue Biopharma, Inc., (CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today Anish Suri, Ph.D., Senior Vice President and Chief Scientific Officer will participate in a panel discussion entitled “Novel Approaches from Biotech,” Session 4, Breakout Track A, at The New York Academy of Sciences (NYAS), Frontiers in Cancer Immunotherapy Conference on Wednesday, May 15 at 1:00 PM ET in New York. Dr. Suri will discuss the Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, including mechanistic data demonstrating the specificity and selectivity of the Immuno-STAT biologics framework and its ability to target tumor-specific T cells and activate them into potent cytotoxic killer T cells.

  • If You Had Bought Cue Biopharma (NASDAQ:CUE) Stock A Year Ago, You'd Be Sitting On A 25% Loss, Today
    Simply Wall St.

    If You Had Bought Cue Biopharma (NASDAQ:CUE) Stock A Year Ago, You'd Be Sitting On A 25% Loss, Today

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is doubtless a positive to see that the Cue Biopharma, Inc. (NASDAQ:CUE) share price has gained...

  • GlobeNewswire

    Cue Biopharma to Present Immuno-STAT Platform Technology at PEGs Boston 2019

    CAMBRIDGE, Mass., April 08, 2019 -- Cue Biopharma, Inc. (NASDAQ: CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to.